Figure_5.tif (340.67 kB)
MZC protects mice against vaginal and anorectal HSV-2 infection.
figure
posted on 2014-04-16, 04:16 authored by Larisa Kizima, Aixa Rodríguez, Jessica Kenney, Nina Derby, Olga Mizenina, Radhika Menon, Samantha Seidor, Shimin Zhang, Keith Levendosky, Ninochka Jean-Pierre, Pavel Pugach, Guillermo Villegas, Brian E. Ford, Agegnehu Gettie, James Blanchard, Michael Piatak Jr, Jeffrey D. Lifson, Gabriela Paglini, Natalia Teleshova, Thomas M. Zydowsky, Melissa Robbiani, José A. Fernández-RomeroA) Depo-treated (vaginal) or untreated (anorectal) Balb/C mice were challenged with 106 pfu HSV-2 10 min after applying the indicated formulations (n = 20/formulation). The percentages of uninfected animals over time, based on symptoms, are shown for each treatment group (*P<0.05 vs. D-PBS and CG, Fisher's exact test). B) Depo-treated Balb/C mice were treated with 10 µl of the indicated formulations intravaginally at different time points before or after HSV-2 challenge with 5×103 pfu (n = 20/formulation). The percentages of uninfected animals are shown for each time of gel dosing relative to challenge (*P<0.05 vs. D-PBS, Fisher's exact test).
History
Usage metrics
Categories
Keywords
microbiologyMedical microbiologyMicrobial pathogensViral pathogensImmunodeficiency viruseshivMicrobial controlantimicrobialsantiviralsAnimal models of infectionVirologyorganismsanimalsvertebratesmammalsprimatesmonkeysOld World monkeysmacaqueInfectious diseasesInfectious disease controlSexually transmitted diseasesViral diseasesPublic and occupational healthpreventive medicineHIV preventionModel organismsAnimal modelsMouse modelsprotectsmicevaginalanorectalhsv-2
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC